Lack of cross-reactivity of Ambien (zolpidem) with drugs in standard urine drug screens

Archives of Pathology & Laboratory Medicine,  Apr 1997  by A A Piergies,  S Sainati,  B Roth-Schechter

• E-mail
• Print
• Link

14. G. D. Searle, Inc. Monthly prescription volume trend data,1/1/95-8/31/ 96. IMS America, Plymouth Meeting, Pa.

15. Guinebault P, Dubruc C, Hermann P Thenot JP High-performance liquid chromatographic determination of zolpidem, a new sleep inducer, in biological fluids with fluorimetric detection. J Chromatogr 1986;383:206-211.

16. Hollander M, Wolfe D. Nonparametric Statistical Methods. New York, NY: John Wiley & Sons; 1987:23-24.

17. Beck O, Latolie P, Hjemdahl P, et al. Detection of benzodiazepine intake in therapeutic doses by immunoanalysis of urine: two techniques evaluated and modified for improved performance. Clin Chem. 1992;38:271-275.

18. Koch TR, Raglin RL, Kirk S, Bruni JE Improved screening for benzodiazepines metabolites in urine using the Triage Panel for Drugs of Abuse. J Anal Toxicol. 1994;18:168-172.

19. Simonsson P, Lindberg J. The effect of beta-glucuronidase on urinary benzodiazepine concentrations as measured by FPIA benzodiazepine assay. Scand l Clin Lab Invest.1994;54(suppl 218):74.

Accepted for publication December 10, 1996.

From the Evanston (III) Hospital, Clinical Pharmacology Unit (Dr Piergies); Lorex Pharmaceuticals, Skokie, III (Dr Sainati); and Boston Research and Science Consulting, Dover, Mass (Dr Roth-Schechter).

Reprint requests to The Evanston Hospital, Clinical Pharmacology Unit, 2650 Ridge Ave, Evanston, IL 60201 (Dr Piergies).

Copyright College of American Pathologists Apr 1997
Provided by ProQuest Information and Learning Company. All rights Reserved